Literature DB >> 12176894

IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.

Yoshihiro Hayakawa1, Kazuyoshi Takeda, Hideo Yagita, Mark J Smyth, Luc Van Kaer, Ko Okumura, Ikuo Saiki.   

Abstract

Alpha-galactosylceramide (alpha-GalCer), which is a specific ligand for CD1d-restricted variable-alpha14 chain (V(alpha)14) natural killer T (NKT) cells, exerts a potent antitumor effect. We recently demonstrated that interferon-gamma (IFN-gamma) secreted by both NKT cells and NK cells plays a critical role in mediating the antimetastatic effect of alpha-GalCer; however, the IFN-gamma-dependent antitumor mechanisms remain poorly defined. In the present study, we demonstrate IFN-gamma-dependent inhibition of tumor angiogenesis by alpha-GalCer. In alpha-GalCer-treated mice, subcutaneous tumor growth and tumor-induced angiogenesis were inhibited in an IFN-gamma-dependent manner. The alpha-GalCer-activated splenic or hepatic mononuclear cells inhibited murine endothelial cell proliferation in vitro, and this inhibitory effect was mediated mostly by IFN-gamma produced by NKT cells and NK cells. NK cell depletion resulted in significant but partial inhibition of tumor growth and angiogenesis in vivo. These results suggest that the IFN-gamma-mediated inhibition of tumor angiogenesis is critically involved in the effector mechanisms of antitumor effects evoked by alpha-GalCer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176894

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.

Authors:  V Vigneshwaran; P Thirusangu; B R Vijay Avin; V Krishna; S N Pramod; B T Prabhakar
Journal:  Clin Exp Immunol       Date:  2017-04-05       Impact factor: 4.330

Review 2.  Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells.

Authors:  Alvaro Arjona; Dipak K Sarkar
Journal:  Neurochem Res       Date:  2007-10-27       Impact factor: 3.996

Review 3.  Harnessing invariant NKT cells in vaccination strategies.

Authors:  Vincenzo Cerundolo; Jonathan D Silk; S Hajar Masri; Mariolina Salio
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 4.  Application of natural killer T-cells to posttransplantation immunotherapy.

Authors:  Shin-ichiro Fujii
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

5.  During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment.

Authors:  Malcolm S Duthie; Stuart J Kahn
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

6.  The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma.

Authors:  Laura Escribà-Garcia; Carmen Alvarez-Fernández; Ana Carolina Caballero; Robert Schaub; Jorge Sierra; Javier Briones
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

7.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

8.  Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.

Authors:  Yoshihiro Hayakawa; Stefania Rovero; Guido Forni; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

9.  Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses.

Authors:  Harlan P Jones; Yi-Chong Wang; Beau Aldridge; Jay M Weiss
Journal:  Cancer Immun       Date:  2008-02-19

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.